FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097777344> ?p ?o ?g. }

• W2097777344 endingPage "1457" @default.
• W2097777344 startingPage "1452" @default.
• W2097777344 abstract "Objectives To compare the safety and efficacy of the daily erectogenic therapy, tadalafil, on lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS) in men with or without comorbid erectile dysfunction (ED). Methods Following a 4-week placebo run-in period, men with moderate-to-severe BPH-LUTS were randomized to placebo or tadalafil 2.5, 5, 10, or 20 mg once daily for 12 weeks. International Prostate Symptom Scores (IPSS), IPSS quality of life, and BPH Impact Index were measured every 4 weeks. Safety was mainly assessed via spontaneous reports of adverse events. Data from men with (n = 716) or without (n = 340) ED at baseline were compared in posthoc analyses. Results Men with ED were older and had more frequent hypertension, hyperlipidemia, coronary artery disease, and diabetes at baseline compared with men without ED. After 12 weeks, changes in IPSS in men with ED (least squares mean change from baseline, placebo: −2.4; tadalafil 2.5, 5, 10, 20 mg: −4.3, −4.8, −5.3, −5.6) and without ED (−2.4, −3.2, −5.3, −5.1, −4.5) were not significantly different (subgroup/interaction P values: .352/.644). Similar effects were observed for IPSS quality of life (with ED: −0.6, −0.9, −0.9, −1.0, −1.1; without ED: −0.6, −0.7, −0.9, −0.8, −0.8; 0.090/0.773) and BPH Impact Index (with ED: −0.7, −0.9, −1.3, −1.3, −1.4; without ED: −1.0, −0.7, −1.3, −1.3, −1.2; 0.753/0.852). Tadalafil was generally well tolerated, and men with or without ED had similar tolerability profiles. Conclusions Changes in BPH-LUTS after 12 weeks of treatment with placebo or various doses of once daily tadalafil were similar in men with or without comorbid ED. To compare the safety and efficacy of the daily erectogenic therapy, tadalafil, on lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS) in men with or without comorbid erectile dysfunction (ED). Following a 4-week placebo run-in period, men with moderate-to-severe BPH-LUTS were randomized to placebo or tadalafil 2.5, 5, 10, or 20 mg once daily for 12 weeks. International Prostate Symptom Scores (IPSS), IPSS quality of life, and BPH Impact Index were measured every 4 weeks. Safety was mainly assessed via spontaneous reports of adverse events. Data from men with (n = 716) or without (n = 340) ED at baseline were compared in posthoc analyses. Men with ED were older and had more frequent hypertension, hyperlipidemia, coronary artery disease, and diabetes at baseline compared with men without ED. After 12 weeks, changes in IPSS in men with ED (least squares mean change from baseline, placebo: −2.4; tadalafil 2.5, 5, 10, 20 mg: −4.3, −4.8, −5.3, −5.6) and without ED (−2.4, −3.2, −5.3, −5.1, −4.5) were not significantly different (subgroup/interaction P values: .352/.644). Similar effects were observed for IPSS quality of life (with ED: −0.6, −0.9, −0.9, −1.0, −1.1; without ED: −0.6, −0.7, −0.9, −0.8, −0.8; 0.090/0.773) and BPH Impact Index (with ED: −0.7, −0.9, −1.3, −1.3, −1.4; without ED: −1.0, −0.7, −1.3, −1.3, −1.2; 0.753/0.852). Tadalafil was generally well tolerated, and men with or without ED had similar tolerability profiles. Changes in BPH-LUTS after 12 weeks of treatment with placebo or various doses of once daily tadalafil were similar in men with or without comorbid ED." @default.
• W2097777344 created "2016-06-24" @default.
• W2097777344 creator A5007216252 @default.
• W2097777344 creator A5033375097 @default.
• W2097777344 creator A5043619141 @default.
• W2097777344 creator A5049019006 @default.
• W2097777344 creator A5083422856 @default.
• W2097777344 creator A5090431664 @default.
• W2097777344 date "2010-06-01" @default.
• W2097777344 modified "2023-10-04" @default.
• W2097777344 title "Effects of Tadalafil on Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men With or Without Erectile Dysfunction" @default.
• W2097777344 cites W1594036338 @default.
• W2097777344 cites W1964130227 @default.
• W2097777344 cites W1967807453 @default.
• W2097777344 cites W1971137611 @default.
• W2097777344 cites W1986031402 @default.
• W2097777344 cites W1995256786 @default.
• W2097777344 cites W1999691104 @default.
• W2097777344 cites W2002651574 @default.
• W2097777344 cites W2009522898 @default.
• W2097777344 cites W2016582498 @default.
• W2097777344 cites W2022912254 @default.
• W2097777344 cites W2023252283 @default.
• W2097777344 cites W2025969930 @default.
• W2097777344 cites W2034349815 @default.
• W2097777344 cites W2035879942 @default.
• W2097777344 cites W2040620026 @default.
• W2097777344 cites W2050093658 @default.
• W2097777344 cites W2070505357 @default.
• W2097777344 cites W2074093603 @default.
• W2097777344 cites W2074917601 @default.
• W2097777344 cites W2078469638 @default.
• W2097777344 cites W2079130657 @default.
• W2097777344 cites W2085095071 @default.
• W2097777344 cites W2085477178 @default.
• W2097777344 cites W2086685901 @default.
• W2097777344 cites W2116228270 @default.
• W2097777344 cites W2145192033 @default.
• W2097777344 cites W2162102173 @default.
• W2097777344 doi "https://doi.org/10.1016/j.urology.2009.09.093" @default.
• W2097777344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20163842" @default.
• W2097777344 hasPublicationYear "2010" @default.
• W2097777344 type Work @default.
• W2097777344 sameAs 2097777344 @default.
• W2097777344 citedByCount "54" @default.
• W2097777344 countsByYear W20977773442012 @default.
• W2097777344 countsByYear W20977773442013 @default.
• W2097777344 countsByYear W20977773442014 @default.
• W2097777344 countsByYear W20977773442015 @default.
• W2097777344 countsByYear W20977773442016 @default.
• W2097777344 countsByYear W20977773442017 @default.
• W2097777344 countsByYear W20977773442018 @default.
• W2097777344 countsByYear W20977773442019 @default.
• W2097777344 countsByYear W20977773442020 @default.
• W2097777344 countsByYear W20977773442021 @default.
• W2097777344 countsByYear W20977773442022 @default.
• W2097777344 countsByYear W20977773442023 @default.
• W2097777344 crossrefType "journal-article" @default.
• W2097777344 hasAuthorship W2097777344A5007216252 @default.
• W2097777344 hasAuthorship W2097777344A5033375097 @default.
• W2097777344 hasAuthorship W2097777344A5043619141 @default.
• W2097777344 hasAuthorship W2097777344A5049019006 @default.
• W2097777344 hasAuthorship W2097777344A5083422856 @default.
• W2097777344 hasAuthorship W2097777344A5090431664 @default.
• W2097777344 hasConcept C121608353 @default.
• W2097777344 hasConcept C126322002 @default.
• W2097777344 hasConcept C126894567 @default.
• W2097777344 hasConcept C142724271 @default.
• W2097777344 hasConcept C159110408 @default.
• W2097777344 hasConcept C197934379 @default.
• W2097777344 hasConcept C204787440 @default.
• W2097777344 hasConcept C27081682 @default.
• W2097777344 hasConcept C2776235491 @default.
• W2097777344 hasConcept C2776547966 @default.
• W2097777344 hasConcept C2777333188 @default.
• W2097777344 hasConcept C2777562237 @default.
• W2097777344 hasConcept C2779478474 @default.
• W2097777344 hasConcept C2779929075 @default.
• W2097777344 hasConcept C2779951463 @default.
• W2097777344 hasConcept C2780816001 @default.
• W2097777344 hasConcept C71924100 @default.
• W2097777344 hasConcept C77411442 @default.
• W2097777344 hasConceptScore W2097777344C121608353 @default.
• W2097777344 hasConceptScore W2097777344C126322002 @default.
• W2097777344 hasConceptScore W2097777344C126894567 @default.
• W2097777344 hasConceptScore W2097777344C142724271 @default.
• W2097777344 hasConceptScore W2097777344C159110408 @default.
• W2097777344 hasConceptScore W2097777344C197934379 @default.
• W2097777344 hasConceptScore W2097777344C204787440 @default.
• W2097777344 hasConceptScore W2097777344C27081682 @default.
• W2097777344 hasConceptScore W2097777344C2776235491 @default.
• W2097777344 hasConceptScore W2097777344C2776547966 @default.
• W2097777344 hasConceptScore W2097777344C2777333188 @default.
• W2097777344 hasConceptScore W2097777344C2777562237 @default.
• W2097777344 hasConceptScore W2097777344C2779478474 @default.
• W2097777344 hasConceptScore W2097777344C2779929075 @default.
• W2097777344 hasConceptScore W2097777344C2779951463 @default.
• W2097777344 hasConceptScore W2097777344C2780816001 @default.

• next